We are live on ! Find out more
IMPL

Impel Pharmaceuticals Inc. Common Stock
IMPL

Delisted

IMPL was delisted on the 15th of December, 2023.

Back to rankings

32 hedge funds and large institutions have $24.8M invested in Impel Pharmaceuticals Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 35 → 32 (-3)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

75% less capital invested

Capital invested by funds: $99.6M → $24.8M (-$74.9M)

Holders
32
Holders Change
-3
Holders Change %
-8.57%
% of All Funds
0.51%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
3
Increased
6
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DA
DCF Advisers
Connecticut
+$137K
2
BCM
Bridgeway Capital Management
Texas
+$71.6K
3
Millennium Management
Millennium Management
New York
+$70.2K
4
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
+$34.4K
5
JP Morgan Chase
JP Morgan Chase
New York
+$6.44K

Top Sellers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
-$535K
2
JGC
J. Goldman & Co
New York
-$286K
3
Citadel Advisors
Citadel Advisors
Florida
-$187K
4
Jane Street
Jane Street
New York
-$49.3K
5
State Street
State Street
Massachusetts
-$29.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
KKRC
1
Kohlberg Kravis Roberts & Co
New York
$5.79M – – –
NA
2
NVP Associates
California
$4.31M – – –
5VM
3
5AM Venture Management
California
$4.04M – – –
VC
4
Vivo Capital
California
$4.04M – – –
VP
5
venBio Partners
California
$3.86M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$720K – – –
LM
7
Lasry Marc
$572K – – –
DA
8
DCF Advisers
Connecticut
$536K +$137K +57,323 +18%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$216K +$363 +152 +0.1%
LCM
10
Laurion Capital Management
New York
$175K – – –
JGC
11
J. Goldman & Co
New York
$112K -$286K -120,000 -60%
BCM
12
Bridgeway Capital Management
Texas
$88.6K +$71.6K +30,000 +90%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$49.4K – – –
Millennium Management
14
Millennium Management
New York
$41K +$70.2K +29,401 New
State Street
15
State Street
Massachusetts
$35.3K -$29.4K -12,300 -33%
EP
16
EPIQ Partners
Minnesota
$26.1K – – –
BlackRock
17
BlackRock
New York
$25.2K +$1.1K +462 +3%
RJA
18
Raymond James & Associates
Florida
$20.3K – – –
CAPTRUST Financial Advisors
19
CAPTRUST Financial Advisors
North Carolina
$20.2K +$34.4K +14,407 New
BJL
20
Brighton Jones LLC
Washington
$19.8K – – –
Northern Trust
21
Northern Trust
Illinois
$18.5K -$327 -137 -1%
Renaissance Technologies
22
Renaissance Technologies
New York
$17K -$7.4K -3,100 -20%
MP
23
McDonald Partners
Ohio
$16.4K – – –
LC
24
Lindbrook Capital
California
$4.28K – – –
JP Morgan Chase
25
JP Morgan Chase
New York
$4K +$6.44K +2,700 +752%
1
2

IMPL Hedge Fund Activity: Q1 2023 in Review

32 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q1 2023, worth a combined $24.8M — down 75% from $99.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of IMPL and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.

The largest buyer was DCF Advisers, adding an estimated $137K. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $535K sold.

  • 32 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q1 2023, down from 35 in Q4 2022.
  • Funds reported $24.8M of Impel Pharmaceuticals Inc. Common Stock stock for Q1 2023, down 75% quarter-over-quarter.
  • 3 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of -2 holders.
  • The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q1 2023 was DCF Advisers, an estimated $137K added.
  • The largest Impel Pharmaceuticals Inc. Common Stock seller in Q1 2023 was Gilder Gagnon Howe & Co, an estimated $535K sold.

Based on aggregated 13F filings for Q1 2023.